Affirm Holdings, Inc. (AFRM)
NASDAQ: AFRM · Real-Time Price · USD
77.28
+2.42 (3.23%)
At close: Aug 6, 2025, 4:00 PM
77.60
+0.32 (0.41%)
After-hours: Aug 6, 2025, 7:58 PM EDT
Revance Therapeutics Stock Forecast
Stock Price Forecast
The 19 analysts that cover Revance Therapeutics stock have a consensus rating of "Buy" and an average price target of $68.68, which forecasts a -11.13% decrease in the stock price over the next year. The lowest target is $45 and the highest is $82.
Price Target: $68.68 (-11.13%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Revance Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 6 | 6 | 7 | 7 | 7 |
| Buy | 8 | 8 | 8 | 8 | 9 | 9 |
| Hold | 8 | 8 | 7 | 7 | 7 | 7 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 21 | 22 | 21 | 22 | 23 | 23 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Susquehanna | Susquehanna | Buy Maintains $65 → $76 | Buy | Maintains | $65 → $76 | -1.66% | Jul 23, 2025 |
| Truist Securities | Truist Securities | Strong Buy Maintains $58 → $72 | Strong Buy | Maintains | $58 → $72 | -6.83% | Jul 22, 2025 |
| Oppenheimer | Oppenheimer | Buy Initiates $80 | Buy | Initiates | $80 | +3.52% | Jul 21, 2025 |
| Deutsche Bank | Deutsche Bank | Strong Buy Initiates $78 | Strong Buy | Initiates | $78 | +0.93% | Jul 17, 2025 |
| Truist Securities | Truist Securities | Strong Buy Maintains $58 → $72 | Strong Buy | Maintains | $58 → $72 | -6.83% | Jul 17, 2025 |
Financial Forecast
Revenue This Year
3.24B
from 2.32B
Increased by 39.35%
Revenue Next Year
3.96B
from 3.24B
Increased by 22.24%
EPS This Year
0.05
from -1.67
EPS Next Year
0.82
from 0.05
Increased by 1,558.68%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 3.4B | 4.2B | 5.3B | |||
| Avg | 3.2B | 4.0B | 4.8B | |||
| Low | 2.9B | 3.5B | 4.2B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 44.3% | 30.6% | 35.0% | |||
| Avg | 39.3% | 22.2% | 21.7% | |||
| Low | 24.2% | 9.3% | 6.6% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 0.12 | 1.74 | 3.39 |
| Avg | 0.05 | 0.82 | 1.76 |
| Low | -0.04 | 0.40 | 1.07 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | 3,432.1% | 314.3% |
| Avg | - | 1,558.7% | 115.0% |
| Low | - | 714.2% | 30.5% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.